IS  >> Vol. 2 No. 2 (May 2014)

    Changes and Significance of Serum Soluble Complement Receptor 2 in Patients with Primary Sjogren’s Syndrome

  • 全文下载: PDF(466KB) HTML    PP.17-22   DOI: 10.12677/IS.2014.22004  
  • 下载量: 2,171  浏览量: 8,515  



原发性干燥综合征可溶性补体受体2Primary Sjogren’s Syndrome Soluble Complement Receptor 2


目的:探讨原发性干燥综合征(pSS)患者血清中可溶性补体受体2(sCR2)的变化及意义。方法:采用ELISA法检测20例原发性干燥综合征患者和20例健康体检者血清中可溶性补体受体2的浓度,并用SPSS统计软件进行相关统计学分析。结果:pSS患者sCR2水平均明显低于健康体检者(P均<0.01),sCR2与年龄和性别无关,特别是PSS患者中抗体阳性组血清sCR2水平低于阴性对照组,存在显著的统计学意义(P < 0.05),而且pSS患者血清sCR2水平与免疫球蛋白IgG及血沉存在明显负相关。结论:pSS患者血清sCR2水平明显降低,且与免疫球蛋白IgG及血沉存在明显负相关,提示sCR2可能参与pSS的发病过程。

Aim: Changes and significance of serum soluble complement receptor 2 (sCR2) in patients with primary Sjogren’s syndrome (pSS) are discussed. Methods: ELISA was developed for the determination of sera sCR2 concentration in sera of 20 pSS patients and 20 healthy volunteers. Statistical analysis was performed by using SPSS software. Results: The level of serum sCR2 in patients with pSS was significantly lower than that in healthy control (P < 0.01). In addition, there was no correlation between patients’ age and sex in sCR2 levels. The level of serum sCR2 in the self-antibody positive group was lower than that in the negative control group, and there was significant statistical significance (P < 0.05). In addition, the level of serum sCR2 in pSS patients showed negative correlation with immunoglobulin IgG and ESR level. Conclusions: The evident decrease of serum sCR2 level in pSS patients has negative correlation with the levels of immunoglobulin IgG and ESR, which suggests that sCR2 may play a critical role in the pathogenesis of pSS.

李宁宁, 张永利, 王晓非, 侯云华, 应晓杨, 王晨辰, 张婷, 刘影, 王芳. 可溶性补体受体2在干燥综合征患者血清中的变化及意义[J]. 免疫学研究, 2014, 2(2): 17-22.


[1] 马大龙 (1998) 补体受体. 国外医学分子生物学分册, 10, 208-212.
[2] Toozc, J.A. and Bcvan, D.H. (1991) Regulator of complement activation. Clinical & Experimental Immunology, 83, 423-429.
[3] Fischer, E., Dclibrias, C. and Kazatchkine, M.D. (1991) Soluble complement receptor. The Journal of Immunology, 146,865-869.
[4] Fcaron, D.T (1991) Primary Sjogren’s syndrome. Clinical & Experimental Immunology, 86, 43-46.
[5] Fox Ri (2005) Sjogren’s syndrome. Lancet, 366, 321-331.
[6] 尹培达, 余步云 (1999) 风湿病. 科学技术文献出版社, 北京.
[7] Ramos-Casals M., Brito-Zeron, P., Siso-Almirall, A., et al. (2002) Topical and systemic medications for the treatment of primary Siogren’s syndrome. Nature Reviews Rheumatology, 8, 399-411.
[8] 苗江永, 张祥建, 刘瑞春, 等 (2004) 帕金森病患者外周血清可溶性补体受体2的变化及意义. 临床荟萃, 19, 1232-1235.
[9] Mollnes, T.E., Lea, T., Mellbye, O.J., Pahle, J., Grand, O. and Harboe, M. (1986) Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis & Rheumatology, 29, 715-721.
[10] Ozaki, K., Spolski, R., Feng, C.G., et al. (2002) A critical role for IL-21 in regulating immunoglobulin production. Science, 298, 1630-1634.